BIFIDO. Co. Ltd Logo

BIFIDO. Co. Ltd

Biotechnology firm developing human-derived Bifidobacterium for various products.

238200 | KO

Overview

Corporate Details

ISIN(s):
KR7238200000
LEI:
Country:
South Korea
Address:
강원도 홍천군 홍천읍 농공단지길 23-16, 홍천군

Description

BIFIDO Co., Ltd. is a biotechnology company established in 1999 that specializes in the human microbiome. The company's core focus is the research and development of human-derived Bifidobacterium strains for use in functional foods, supplements, and personal care products. BIFIDO operates an integrated platform that covers the entire process from the selection of probiotic and pharmabiotic candidates to the manufacturing of finished goods, marketed under brands like BIFIDOLAB. Its research, supported by extensive scientific papers and patents, targets areas such as immune regulation, cognitive health, and the development of microbiome-based therapeutics for various health conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-08-30 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 74.9 KB
2024-08-30 00:00
기타시장안내 (상장적격성 실질심사 사유 추가)
Korean HTML 2.9 KB
2024-08-30 00:00
기타시장안내 (개선계획서 제출)
Korean HTML 3.6 KB
2024-08-14 00:00
반기보고서 (2024.06)
Korean HTML 1.0 MB
2024-08-08 00:00
기타시장안내 (상장적격성 실질심사 대상 결정 )
Korean HTML 4.4 KB
2024-08-08 00:00
주권매매거래정지기간변경 (상장적격성 실질심사 대상 결정)
Korean HTML 4.8 KB
2024-07-18 00:00
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean HTML 3.2 KB
2024-07-17 00:00
[기재정정]횡령ㆍ배임혐의발생
Korean HTML 10.3 KB
2024-07-11 00:00
주식등의대량보유상황보고서(약식)
Korean HTML 56.1 KB
2024-07-10 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean HTML 16.2 KB
2024-07-09 00:00
단기차입금증가결정
Korean HTML 9.0 KB
2024-07-01 00:00
전환가액의조정
Korean HTML 11.2 KB
2024-07-01 00:00
횡령ㆍ배임혐의진행사항
Korean HTML 5.9 KB
2024-06-28 00:00
기타시장안내 (업종변경 안내)
Korean HTML 4.6 KB
2024-06-27 00:00
주권매매거래정지 (상장적격성 실질심사 대상 (사유발생))
Korean HTML 4.6 KB

Automate Your Workflow. Get a real-time feed of all BIFIDO. Co. Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIFIDO. Co. Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIFIDO. Co. Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celemics, Inc. Logo
Develops NGS target enrichment solutions for research and clinical applications.
South Korea
331920
Develops radiopharmaceuticals and radioligand therapies for oncology.
South Korea
308430
CELL BIOTECH CO ., LTD Logo
Develops and manufactures probiotic solutions using patented dual-coating technology.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based immunotherapies for severe inflammatory and allergic diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.
United States of America
CLRB
Cellectis Logo
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
France
ALCLS
Cellid Co., Ltd. Logo
Develops immunotherapeutic vaccines for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Researches and develops health foods, derma-cosmetics, and OTC pharmaceuticals.
South Korea
471820
CellSeed Inc. Logo
Develops and commercializes cell sheet engineering for regenerative medicine.
Japan
7776
Celltrion, Inc. Logo
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
South Korea
068270

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.